Commercial and scientific update
ProBiotix Health is a subsidiary of AIM listed OptiBiotix. OptiBiotix was formed in March 2012 by Stephen O’Hara, the Company’s Chief Executive, to develop compounds which modify the human microbiome to prevent and manage human disease.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform
technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
OptiBiotix has a strategy of bringing its divisions to maturity, through scientific development, to create self-sustaining commercial entities with the potential for an exit or public listing.
In support of this strategy, OptiBiotix established ProBiotix in 2018, recognising that its probiotics business had achieved sufficient scientific and commercial maturity, with rapidly growing revenue streams, to justify a standalone commercial operation.
On 31 March 2022, ProBiotix Health acquired ProBiotix in a share for share exchange.
ProBiotix Health anticipating "big commercial opportunities" during 2023
Group CEO Stephen O’Hara and CEO Steen Anderson | 04 January 2023